To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones
mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …

Clonal hematopoiesis (CH) results from somatic genomic alterations that drive clonal
expansion of blood cells. Somatic gene mutations associated with hematologic …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Classical Hodgkin lymphoma (cHL) is unique among lymphoid malignancies in several key
biological features.(i) The Hodgkin and Reed-Sternberg (HRS) tumor cells are rare among …

Cancer has a high mortality rate across the globe, and tissue biopsy remains the gold
standard for tumor diagnosis due to its high level of laboratory standardization, good …

The scarcity of malignant Hodgkin and Reed–Sternberg cells hampers tissue-based
comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid …

PURPOSE Clinical outcomes of patients with CNS lymphomas (CNSLs) are remarkably
heterogeneous, yet identification of patients at high risk for treatment failure is challenging …

The clinical development of effective cancer immunotherapies, along with advances in
genomic analysis, has led to the identification of tumor environmental features that predict …